Boston's resTORbio Sets Terms for $85M IPO Post author:Sam Post published:January 16, 2018 Post category:BioPharma resTORbio is developing novel therapies to improve immune function in the elderly. Source: BioSpace You Might Also Like Presbia Announces Extension Of Rights Offering February 22, 2017 Stanford, NCI Researchers Discover New CAR-T Target With Early Study Data November 20, 2017 3 Big Drugmakers With Huge Catalysts on the Horizon January 30, 2018
